CB-839
About us
CB-839 an is orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and irreversibly inhibits glutaminase, a mitochondrial enzyme that is essential for the conversion of the amino acid glutamine into glutamate. By blocking glutamine utilization, proliferation in rapidly growing cells is impaired. Glutamine-dependent tumors rely on the conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). ( )
https://www.bocsci.com/cb-839-cas-1439399-58-2-item-462472.html
Is this your business?
Featured businesses
604 3rd ave, New York, New York, 10016
(347) 559-0871
110 Chambers Street, New York, New York, 10007
(212) 933-4737